Zhao Jingru, Zhang Xiangjian, Dong Lipeng, Wen Ya, Cui Lili
Department of Neurology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China; ; Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei 050051, China.
Department of Neurology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China; ; Hebei collaborative innovation center for cerebro-vascular disease, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China ; Hebei Key Laboratory for Neurology, Shijiazhuang, Hebei 050000, China.
Curr Neuropharmacol. 2014 Dec;12(6):564-74. doi: 10.2174/1570159X12666140923210929.
Stroke is the third leading cause of human death. Endothelial dysfunction, thrombogenesis, inflammatory and oxidative stress damage, and angiogenesis play an important role in cerebral ischemic pathogenesis and represent a target for prevention and treatment. Statins have been found to improve endothelial function, modulate thrombogenesis, attenuate inflammatory and oxidative stress damage, and facilitate angiogenesis far beyond lowering cholesterol levels. Statins have also been proved to significantly decrease cardiovascular risk and to improve clinical outcome. Could statins be the new candidate agent for the prevention and therapy in ischemic stroke? In recent years, a vast expansion in the understanding of the pathophysiology of ischemic stroke and the pleiotropic effects of statins has occurred and clinical trials involving statins for the prevention and treatment of ischemic stroke have begun. These facts force us to revisit ischemic stroke and consider new strategies for prevention and treatment. Here, we survey the important developments in the non-lipid dependent pleiotropic effects and clinical effects of statins in ischemic stroke.
中风是人类死亡的第三大主要原因。内皮功能障碍、血栓形成、炎症和氧化应激损伤以及血管生成在脑缺血发病机制中起重要作用，是预防和治疗的靶点。已发现他汀类药物不仅能降低胆固醇水平，还能改善内皮功能、调节血栓形成、减轻炎症和氧化应激损伤以及促进血管生成。他汀类药物也已被证明能显著降低心血管风险并改善临床结局。他汀类药物能否成为缺血性中风预防和治疗的新候选药物？近年来，人们对缺血性中风病理生理学和他汀类药物多效性的认识有了极大扩展，涉及他汀类药物预防和治疗缺血性中风的临床试验已经开始。这些事实促使我们重新审视缺血性中风并考虑新的预防和治疗策略。在此，我们综述他汀类药物在缺血性中风中非脂质依赖性多效性作用和临床效果的重要进展。
